A Phase 1 interventional study of Dexlansoprazole in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-10.
Sponsored by Takeda · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the pharmacokinetics after a single dose of dexlansoprazole 30 and 60 mg delayed-release capsules in healthy Chinese participants.
The drug being tested in this study is called Dexlansoprazole. This study will assess the pharmacokinetics, safety and tolerability of a single oral dose of Dexlansoprazole 30 mg and 60 mg delayed-release capsules in healthy participants.
The study will enroll approximately 40 participants, 20 participants in each parallel arm. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:
All participants will be asked to take single dose of study drug on Day 1.
This single center trial will be conducted in China. The overall time to participate in this study is approximately 40 days. Participants will be contacted by telephone or will make a final visit to the clinic 5 to 10 days after receiving their last dose of study drug for a follow-up assessment.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dexlansoprazole 30 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
Drug: Dexlansoprazole
Dexlansoprazole 60 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
Drug: Dexlansoprazole
Dexlansoprazole delayed-release capsule.
Also known as: TAK-390 Modified Release (TAK-390MR) dexlansoprazole
Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole
Time frame: Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Dexlansoprazole
Time frame: Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Dexlansoprazole
Time frame: Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose
Participants took part in the study at 1 investigative site in China from 22 November 2017 to 08 February 2018.
| Milestone | Group 1: Dexlansoprazole 30 mg | Group 2: Dexlansoprazole 60 mg |
|---|---|---|
| Started | 20 | 20 |
| Completed | 20 | 20 |
| Not completed | 0 | 0 |
| nanogram per milliliter (ng/mL) | Group 1: Dexlansoprazole 30 mg | Group 2: Dexlansoprazole 60 mg |
|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole | 732 ± 43.73 | 1756 ± 45.83 |
| hour*nanogram per milliliter (h*ng/mL) | Group 1: Dexlansoprazole 30 mg | Group 2: Dexlansoprazole 60 mg |
|---|---|---|
| AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Dexlansoprazole | 3660 ± 61.38 | 10198 ± 61.09 |
| h*ng/mL | Group 1: Dexlansoprazole 30 mg | Group 2: Dexlansoprazole 60 mg |
|---|---|---|
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Dexlansoprazole | 3701 ± 62.83 | 10340 ± 64.20 |
Collected over Baseline up to 30 days after last dose (Day 31). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Dexlansoprazole 30 mg | 0/20 (0%) | 0/20 (0%) | 3/20 (15%) |
| Group 2: Dexlansoprazole 60 mg | 0/20 (0%) | 0/20 (0%) | 1/20 (5%) |
| Event | Group 1: Dexlansoprazole 30 mg | Group 2: Dexlansoprazole 60 mg |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/20 | 1/20 |
| Alanine aminotransferase increasedInvestigations | 1/20 | 0/20 |
| Blood bilirubin increasedInvestigations | 1/20 | 0/20 |
| White blood cells urineInvestigations | 1/20 | 0/20 |
The safety analysis set included all participants who were enrolled in the study and received at least 1 dose of study drug.
| Age, Continuous(years) | Group 1: Dexlansoprazole 30 mg | Group 2: Dexlansoprazole 60 mg | Total |
|---|---|---|---|
| Mean | 29.4 ± 6.73 | 29.4 ± 5.66 | 29.4 ± 6.14 |
| Sex: Female, Male(Participants) | Group 1: Dexlansoprazole 30 mg | Group 2: Dexlansoprazole 60 mg | Total |
|---|---|---|---|
| Female | 12 | 7 | 19 |
| Male | 8 | 13 | 21 |
| Race and Ethnicity Not Collected(Participants) | Group 1: Dexlansoprazole 30 mg | Group 2: Dexlansoprazole 60 mg | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Group 1: Dexlansoprazole 30 mg | Group 2: Dexlansoprazole 60 mg | Total |
|---|---|---|---|
| China | 20 | 20 | 40 |
| Height(centimeter) | Group 1: Dexlansoprazole 30 mg | Group 2: Dexlansoprazole 60 mg | Total |
|---|---|---|---|
| Mean | 165.88 ± 7.688 | 167.38 ± 7.720 | 166.63 ± 7.642 |
| Weight(kilogram) | Group 1: Dexlansoprazole 30 mg | Group 2: Dexlansoprazole 60 mg | Total |
|---|---|---|---|
| Mean | 61.22 ± 8.469 | 62.43 ± 8.542 | 61.82 ± 8.418 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Group 1: Dexlansoprazole 30 mg | Group 2: Dexlansoprazole 60 mg | Total |
|---|---|---|---|
| Mean | 22.17 ± 1.808 | 22.22 ± 1.911 | 22.20 ± 1.836 |
| Smoking Classification(Participants) | Group 1: Dexlansoprazole 30 mg | Group 2: Dexlansoprazole 60 mg | Total |
|---|---|---|---|
| Never smoked | 15 | 17 | 32 |
| Ex-Smoker | 5 | 3 | 8 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Feb 2018, 2 months.
Results were first posted in May 2019, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexlansoprazole